



NeuroVista Completes Initial Enrollment in Australian Clinical Study

Seattle, WA—November 30, 2010—NeuroVista Corporation, a developer of innovative medical technologies for the management and treatment of epilepsy, today announced completion of patient enrollment in their first clinical study to evaluate the safety and effectiveness of the NeuroVista[®] Seizure Advisory System[™] in patients with medically refractory epilepsy.

A total of 10 subjects were implanted with the NeuroVista system at three leading medical centers in Melbourne, Australia: St. Vincent's Hospital, Austin Hospital, and the Royal Melbourne Hospital. The NeuroVista Seizure Advisory System is designed to provide people living with epilepsy with information about their current likelihood of experiencing a seizure based on the patient's own electroencephalograph (EEG) data. Uncertainty about when seizures are going to strike has been identified as a leading cause of disability for people living with medically refractory epilepsy. Seizure advisory information is intended to enable people living with epilepsy to reduce injuries and engage more fully and confidently in daily activities.

“Completion of enrollment for our clinical study to evaluate the safety and effectiveness of the NeuroVista Seizure Advisory System is a significant milestone that has taken over five years of research and engineering development efforts to achieve,” said John F. Harris, President and Chief Executive Officer of NeuroVista. “With this latest milestone complete, we are one step closer to being able to provide this life-changing technology for patients living with medically refractory epilepsy.”

“The device has proven to be well tolerated,” said Dr. Sam Berkovic, Austin Hospital. “Additionally, the quality of the EEG is remarkable over long periods.”

About NeuroVista

NeuroVista is a clinical stage medical device company pioneering new technologies that will revolutionize the management and treatment of epilepsy. Epilepsy is a neurological condition affecting approximately 1% of the U.S. population—more than Parkinson's disease, multiple sclerosis, and Lou Gehrig's disease combined. NeuroVista is a privately held company based in Seattle. For more information, visit www.neurovista.com.